The information in news releases is current at the time of the release. Note that the information shown here may not be latest information (termination of production or sales, changes to specifications or pricing, organizational or contact address changes, etc.), and may be subject to change without prior notice.
Announcement on the start of patient enrollment for phase III clinical study in Japan of the antiviral drug favipiravir for ixodid tick-borne infectious disease, serious fever with thrombocytopenia syndrome (SFTS)
|March 12, 2018|
Toyama Chemical Co., Ltd. (Head Office: Shinjuku-ku, Tokyo; President: Junji Okada), a FUJIFILM Company, has announced that it has started to enroll patients for phase III clinical study in Japan of the antiviral drug favipiravir for ixodid tick-borne infectious disease, serious fever with thrombocytopenia syndrome (SFTS).
Toyama Chemical has now started to enroll patients in a domestic phase III clinical study of the antiviral drug favipiravir for SFTS. The company will aim to develop and provide a new treatment method for SFTS, for which only supportive therapy is currently available.
Toyama Chemical, a subsidiary of FUJIFILM Holdings Corporation, specializes in pharmaceutical research and development, and strives to contribute to the further development of global health care through new drug development.
* A clinical research which was adopted and conducted by the Research Program on Emerging and Re-emerging Infectious Diseases (Title of research and development: “Research on the diagnostic, therapeutic, and preventive measures' development for and on the infection risk factors' analyses on severe fever with thrombocytopenia syndrome.”) of the Japan Agency for Medical Research and Development (AMED).
About favipiravir (brand name: AVIGAN® Tablet):
About severe fever with thrombocytopenia syndrome (SFTS):